Search

Author/Creator Quast, Daniel R.

1. Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment. Issue 5 (21st January 2022)

Authors:
Meier, Juris J.; Quast, Daniel R.; Nauck, Michael A.; Schenker, Nina; Deacon, Carolyn F.; Holst, Jens J.; Plum‐Mörschel, Leona; Kapitza, Christoph
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 5(2022)
Page Start:
806
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes. Issue 10 (16th July 2021)

Authors:
Quast, Daniel R.; Nauck, Michael A.; Schenker, Nina; Menge, Björn A.; Kapitza, Christoph; Meier, Juris J.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 23:Issue 10(2021)
Page Start:
2344
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin: An update including recently developed glucagon‐like peptide‐1 (GLP‐1) receptor agonists and the glucose‐dependent insulinotropic polypeptide/GLP‐1 receptor co‐agonist tirzepatide. Issue 5 (8th February 2023)

Authors:
Nauck, Michael A.; Mirna, Abd El Aziz; Quast, Daniel R.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 25:Issue 5(2023)
Page Start:
1361
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗